Cocrystal Pharma, Inc. — Director's Dealing 2014

Aug 13, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2014-08-11

Reporting Person: FROST PHILLIP MD ET AL (N/A)
Reporting Person: Frost Gamma Investments Trust (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-08-11	Common Stock	P	45000	$0.2891	Acquired	12276525	Indirect
2014-08-12	Common Stock	P	66200	$0.2930	Acquired	12342725	Indirect

Footnotes

F1: The weighted average price was $0.2891. These shares were purchased in multiple transactions ranging from $0.285 to $0.29, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.

F2: Since the reporting person's last report, 3,591,335 shares previously held by The Frost Group, LLC., a limited liability company of which Frost Gamma Investments Trust is a principal member, have been distributed and are now owned by Frost Gamma Investments Trust.

F3: These securities are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F4: The weighted average price was $0.2930. These shares were purchased in multiple transactions ranging from $0.2889 to $0.30, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (4) to this Form 4.